Fast Market Research announces the availability of the new GBI Research report, "COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands", on their comprehensive research portal

Boston, MA -- (SBWire) -- 01/08/2016 --Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression.

Get More Details on this Report and a Full Table of Contents at COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands

There are currently 203 products in active development, excluding four with an unknown stage of development. Although many of the targets identified in the pipeline are well established in the management of COPD, there are some novel, first-in-class targets. This reflects the growing understanding of the underlying mechanisms that characterize the disease.

Scope

The COPD market has benefited from notable additions over recent years.

-Which classes of drug dominate the market?
-What additional benefits have newly approved therapies brought to market?
-How do the leading marketed therapies compare clinically?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.

-Which molecular targets appear most frequently in the pipeline?
-How will the new therapies be positioned in the treatment of COPD?
-How have selected late-stage pipeline therapies performed in clinical trials?

COPD clinical trials have an overall attrition rate of 89.6%.

-What are the failure rates for individual Phases of clinical development?
-How do COPD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?

The COPD market is forecast to rise from a value of $9.2 billion in 2014 to $11.2 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed.

-How much of a role will disease prevalence and new product approvals play in market growth?
-Will generic competition have a significant impact on the market over the forecast period?

There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006.

-Which territories show the most deal activity?
-What were the trends in deal completion by product stage of development?
-What were the conditions of the key licensing or co-development deals to take place in COPD?

Reasons to Get This Report

This report will allow you to -

-Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.

-Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.

-Analyze the COPD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

-Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

-Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
-Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments
-Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth
-Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
-Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs